Credit Suisse Sees All Eyes On Eyeguard B Data for XOMA

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $5.00 price target on

. In the report, Credit Suisse noted, "We anticipate that the final event in the EYEGUARD B trial will occur soon, and this will trigger an approximate six-week clock to top-line data release. Newly announced positive data in scleritis is encouraging and points to continued activity of gevokizumab across different inflammatory indications. Our 2015 EPS decreases to ($0.55) from ($0.50) based on 2015 guidance." XOMA closed on Wednesday at $3.72.